R&D : Projects

From its platform, Vaxinano develops as a leader:

• An anti-parasitic vaccine against fatal, chronic and congenital toxoplasmosis for which there is currently no treatment or vaccine for humans.
• Immunotherapeutic treatment to cure leishmaniasis. This vaccine platform is also used in collaboration to prevent against influenza and Covid-19. Our nasally administered nanoparticle vaccine candidates have been shown to protect against both infection and transmission of these viruses.

Cette plateforme vaccinale est également utilisée en collaboration pour prévenir contre la grippe et la Covid-19. Il a été montré que nos candidats vaccins nanoparticulaires, administrés par voie nasale, protègent à la fois de l’infection et de la transmission de ces virus